Industry leaders at BIO 2025 highlighted Europe's rich scientific innovation contrast with challenges in business integration, clinical trials, and fundraising compared to the U.S. Fragmented hubs and cultural differences focusing on science over commercialization hamper European biotech’s full market potential. Panelists emphasized the need for streamlined ecosystems, earlier product-market orientation, and tapping available capital to transform scientific leadership into global investment successes within Europe’s biotech sector.